Corteva Q4 sales fall 2% to $3.91 billion, GAAP loss $537 million; full-year profit rises 40%
Corteva reported fourth-quarter 2025 net sales of $3.91 billion, down 2%, and a GAAP loss from continuing operations of $537 million, or $0.80 per share. For full-year 2025, net sales rose 3% to $17.40 billion and GAAP income from continuing operations rose 40% to $1.20 billion, or $1.75 per share. The company also expects 2026 operating EBITDA of $4.0 billion to $4.2 billion and operating EPS of $3.45 to $3.70 per share.
Key points
- Q4 2025 operating EPS was $0.22, down 31% from the prior year, and operating EBITDA was $446 million, down 15%.
- FY 2025 operating EPS was $3.34, up 30%, and free cash flow was $2.9 billion, a 69% improvement.
- A Bayer litigation resolution involves a $610 million cash outflow, largely in the first quarter of 2026.
- Corteva remains on track to complete its planned separation in the second half of 2026.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 03, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.